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Purpose. Osteocytes play a central role in the regulation of bone remodeling. The aim of this 
study was to explore osteocyte function, and particularly the expression of SOST, a Wnt 
inhibitor, in patients with hip fractures. 
Methods. Serum sclerostin levels were measured by ELISA. The expression of several 
osteocytic genes was studied by quantitative PCR in trabecular samples of the femoral head of 
patients with hip fractures, hip osteoarthritis and controls. The presence of sclerostin protein 
and activated caspase 3 was revealed by immunostaining 
Results. There were no significant differences in serum sclerostin between the three groups. 
Patients with fractures have fewer lacunae occupied by osteocytes (60±5 % vs. 64±6 % in 
controls, p=0.014) and higher numbers of osteocytes expressing activated caspase 3, a marker 
of apoptosis. The proportion of sclerostin-positive lacunae was lower in patients with fractures 
than in controls (34±11% vs. 69±10 %, p=2x10-8). The proportion of sclerostin-positive 
osteocytes was also lower in patients. RNA transcripts of SOST , FGF23 and PHEX were also 
less abundant in fractures than in control bones (p=0.002, 5x 10-6, and 0.04, respectively). On 
the contrary, in patients with osteoarthritis, there was a decreased expression of SOST and 
FGF23, without differences in PHEX transcripts or osteocyte numbers. 
Conclusions. Osteocyte activity is altered in patients with hip fractures, with increased 
osteocyte apoptosis and reduced osteocyte numbers, as well as decreased transcription of 
osteocytic genes. Therefore, these results suggest that an osteocyte deficiency may play a role 
in the propensity to hip fractures.  
 





After the seminal studies showing that gain-of-function and loss-of-function mutations of the 
Wnt co-receptor lipoprotein related peptide 5 (LRP5) are associated with marked changes of 
opposite direction in bone mass, the Wnt pathway has been recognized as an important bone 
anabolic stimulus, influencing bone remodelling and fracture repair [1;2].  Binding of Wnt 
ligands to their receptors induce the disassembly of the GSK3 complex that phosphorylates β-
catenin. Since non-phosphorylated β-catenin is less prone to proteasome degradation, this 
results in increased β-catenin levels and translocation into the nucleus, where it modulates the 
transcription of target genes [3;4]. 
Osteocytes are the most abundant cells in bone. They derive from osteoblasts that become 
embedded within the bone matrix laid during the bone formation phase of bone remodelling. 
Although initially regarded as a passive process, it is now clear that the osteoblast-osteocyte 
transition is an organized process that includes specific changes in the gene expression pattern. 
Osteocytes are nowadays recognized as major players in the regulation of bone remodelling. 
They are considered as the cells transducing the effects of mechanical forces acting on bone, 
able to mark the skeletal areas where a new remodelling cycle is to be initiated, and with 
strong influence on bone formation [5-7]. In fact, osteocytes synthesize several molecules able 
to modulate osteoblast function, including prostaglandins, sclerostin and dickkopf 1 (DKK1). 
Sclerostin, the product of the SOST gene, and DKK1 are potent inhibitors of the Wnt pathway.  
We have previously reported that, in comparison with patients with osteoarthritis (OA), the 
expression of a number of genes in the Wnt pathway is reduced in bone samples from patients 
with osteoporotic hip fractures, suggesting that differences in Wnt activity may be involved in 
the opposite changes in bone mass typical of these disorders. However, we did not find 
significant differences in DKK1 expression between both groups of patients [8].  
On the basis of those data, we hypothesized that an osteocyte dysfunction with increased 
expression of sclerostin could be involved in the reduced Wnt activity found in hip fractures. 
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Therefore, in the present study we determined the expression of sclerostin and other genes 
characteristic of an osteocytic phenotype, as well as osteocyte distribution in patients with hip 
fractures, comparing the results with those in hip OA and control bones. 
 
MATERIALS AND METHODS 
Bone samples 
Bone samples were obtained during hip replacement surgery, in patients over 50 years of age 
with hip fractures (Frx) or hip OA, who provided informed consent. Patients with secondary 
osteoporosis, fractures due to high-energy trauma or secondary OA were excluded. Control 
samples were obtained at autopsy of patients without known bone disorders. The study was 
approved by the Institutional Ethics Committee. Trabecular bone cylinders of the central part 
of the femoral head (thus avoiding the fractured and the subchondral regions) were obtained 
with a trephine, washed extensively in phosphate-buffered saline and either snap-frozen in 
liquid nitrogen and stored at -70º until RNA analysis, or processed for histology and 
immunohistochemistry (bones used for both procedures largely but incompletely overlapped, 
due to sample availability) .  
Quantitation of gene expression and sclerostin serum levels 
Bone samples from 18 patients with fractures (13 women and 5 men, mean age 82±5 yr),  21 
with hip osteoarthritis (16 women and 5 men; age 72±7 yr) and 10 controls (4 women and 6 
men; age 79±6 yr) were used. RNA was isolated from bone samples by using Trizol, following 
manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA) and purified using the RNeasy 
kit (Qiagen, Hilden, Germany), as previously reported [9]. 
Aliquots of RNA were reverse-transcribed with the Superscript III kit (Invitrogen), using 
random hexamers as primers. Then, the expression of three genes mainly expressed by 
osteocytes (SOST/sclerostin, fibroblast growth factor 23 [FGF23], and phosphate regulating 
endopeptidase homolog, X-linked [PHEX]) was determined by real-time PCR using gene-
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specific primers and Taqman probes (Applied Biosystems, Foster City, CA, USA). The 
threshold cycle (Ct) for each well was determined. The results were normalized to the 
expression of the housekeeping gene TATA box protein (TBP). Relative gene expression was 
calculated as 2 -Ct, where ΔCt is the difference between the gene of interest threshold cycle and 
the TBP threshold cycle. 
Serum sclerostin levels were measured in patients with hip fractures (n=16, age 78±3 yr) or 
hip OA (n=16, age 76±4), and in control healthy individuals without osteoporosis or other 
disorders affecting skeletal homeostasis (n=12, age 78±3), using a commercial ELISA kit 
(Tecomedical, Sissach, Switzerland), with a sensitivity of 0.15 ng/ml.   
Histology and immunostaining 
Trabecular samples from the femoral heads of 21 patients with fractures (17 women, 4 men; 
mean age 82±9 yr), 8 with hip OA (4 women, 4 men; age 75±4 yr) and 8 controls (4 women, 4 
men; age 79±6 yr) were fixed in 4% formalin for 3 days, decalcified with 20% EDTA for 3 
weeks, and embedded in paraffin. Four-micron thick sections were cut and mounted on 
gelatine-coated slides. Prior to staining, slides were heated for 20 minutes at 60°C,  hydrated 
through graded alcohols, immersed in 50mM sodium citrate buffer for 15 minutes for antigen 
unmasking, and incubated in 0.3% hydrogen peroxide in methanol for 30 minutes to quench 
the endogenous peroxidase activity. After blocking non-specific binding with normal goat 
serum, the slides were incubated overnight with a rabbit polyclonal anti-sclerostin antibody 
(Santa Cruz, Heidelberg, Germany), diluted 1/200,  followed by a secondary biotinylated anti 
rabbit antibody and then with avidin-biotinylated horseradish peroxidase and DAB substrate, 
following manufacturer’s instructions (ABC Peroxidase Rabbit Staining kit; Pierce, Rockford, 
IL, USA).  Slides were counterstained with haematoxylin for 1 minute prior to mounting and 
examined at 400x magnification. Osteocytic lacunae (raw and normalized to the trabecular 
bone area), as well as the presence or absence of osteocytes and sclerostin staining were 
counted in 16 random fields. The distance from the osteocytic lacunae to the closest trabecular 
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surface was measured with a scale grid. Apoptotic osteocytes were identified by using a 
similar protocol with an anti-activated caspase 3 antibody (R&D Systems, Minneapolis, MN, 
USA) diluted 1/100. Appropriate negative control slides without the primary antibodies were 
prepared. The proportion of lacunae occupied by osteocytes, and the proportions of lacunae 
and osteocytes with staining for sclerostin and activated caspase were calculated. All analyses 
were done blindly, without prior knowledge of the group of the sample.  
Statistical analyses 
The statistical significance of the differences in gene expression was tested by the Kruskal-
Wallis test, followed by pair-wise posthoc Mann-Whitney tests, if the global test was 
significant. To compare the results of the histological and immunohistochemical studies, we 
used an ANOVA test, followed by t-test if significant results were found by ANOVA, with or 
without assumption of equal variances according to the Levene test. Prism and SPSS packages 
were used in the analyses.  All reported p-values are two-tailed.    
    
RESULTS 
Serum sclerostin levels and gene expression in bone 
All individuals had detectable serum sclerostin levels. However, we could not demonstrate the 
hypothesized increase in serum sclerostin in patients with fractures. In fact, in comparison with 
patients with OA and control individuals, patients with fractures showed a non significant 
trend to lower sclerostin levels. The mean (±SD) values were 0.78±0.17, 0.80±0.46 and 
0.71±0.30 ng/ml, in control individuals, patients with OA and patients with fractures, 
respectively (fig. 1).  At the bone tissue level there were significant differences in sclerostin 
gene expression across the three groups of individuals (p=0.020). In pair-wise comparisons, 
SOST expression was lower in patients with fractures than in controls (p=0.002), whereas 
similar levels were found in fracture and OA samples (p=0.69) (fig. 2). 
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Given the well-known inhibitory effect of sclerostin on bone formation, those results were 
unexpected. Therefore, we explored the transcript abundance of other genes typically 
expressed in osteocytes, such as FGF23 and PHEX (fig. 2). We also found marked differences 
in the transcript levels of these genes across the groups of patients studied (p=0.00004 and 
p=0.035, for FGF23 and PHEX, respectively). Patients with fractures had lower FGF23 
expression levels than either controls or patients with hip OA (p=0.000005 and 0.003, 
respectively). The average PHEX transcript abundance was also lower in patients with 
fractures than in the other groups (p=0.04 versus controls¸ p=0.02 versus OA). 
There was a direct correlation between FGF23 and PHEX expression in the three study groups 
(p= 0.0001). However, SOST expression did not correlate with FGF23 or PHEX expression. 
Osteocyte distribution and immunohistochemistry 
The above-mentioned results suggested the existence of an overall osteocyte dysfunction in 
patients with fractures. Therefore, we analyzed osteocyte numbers and sclerostin 
immunoreactivity in bone biopsies to elucidate whether it was due to a decreased number of 
osteocytes or to a qualitative defect. 
There were no differences in the number of osteocytic lacunae, adjusted by trabecular bone 
surface, between the three groups studied (p=0.2). After immunostaining of trabecular bone 
samples, sclerostin was detected only in osteocytic lacunae and along osteocytic canaliculi. 
Sclerostin-positive lacunae tended to be located in deeper layers of bone than sclerostin-
negative lacunae. This was a consistent and highly significant finding in all groups, but 
without differences in the depth of sclerostin-positive lacunae across groups (fig. 3).  
The proportion of sclerostin-positive lacunae showed wide individual variations but was much 
lower in patients with fractures than in controls (34±11 % vs. 69±10 %, p= 2x10-8). It also 
showed a non-significant trend for lower values in fractures than in OA (34±11 % vs. 44±21 
%, p=0.2) (fig. 4). Sclerostin immunostaining was found in some osteocyte-containing lacunae 
and also in some empty lacunae. When only the occupied lacunae were considered, there were 
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also marked differences across groups: the proportion of sclerostin-positive osteocytes was 
35±14 % in patients with fractures and 69±10 % in controls (p=1x10-6).   
Patients with fractures had fewer occupied lacunae (i.e., lacunae with an osteocyte inside). The 
proportion of occupied lacunae was 60±5 % in fractures, 64±6 % in controls (p=0.014 vs. 
fractures) and 73±9 % in OA (p=0.005 vs. fractures). This was associated with more frequent  
activated caspase 3 immunostaining, a marker of apoptosis, in fractures (fig 4). The proportion 
of caspase-positive lacunae was 53±8 % in fractures, 41± 6 % in controls (p=0.002) and 40±6 
in OA (p=0.001 vs. fractures). In fact, there was an inverse correlation between the proportion 
of occupied lacunae and those with caspase-positive staining (r=-0.46, p=0.015).  
The average time between fracture and surgery was 4 days (range 0-9). There were no 
correlations between the surgery delay and the proportions of empty lacunae, sclerostin-
positive lacunae or caspase-positive osteocytes (data not shown).  No significant associations 
existed with sex or age. Therefore, similar results were obtained in the sex-stratified analyses 
(not shown).  
The main differences in tissue-level parameters across the groups are summarized in figure 5. 
 
DISCUSSION 
The activation of the Wnt pathway is an important stimulus for bone formation. We have 
previously reported a reduced expression of several genes of the Wnt pathway in bone from 
patients with hip fractures [8], but the mechanisms involved remained unclear. Sclerostin is a 
secreted protein that binds to LRP5/6 and prevents the effective interaction of this co-receptor 
with its ligands of the Wnt family [10-12]. Its role was emphasized by the identification of 
SOST (the gene encoding sclerostin) mutations in patients with Van Buchem disease and 
sclerosteosis, disorders characterized by a markedly increased bone mass [13]. In line with this 
idea, neutralizing anti-sclerostin antibodies have been shown to increase bone formation in 
experimental models of osteoporosis [14], as well as in short-term studies in humans [15]. In 
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this study we confirmed that sclerostin is abundantly expressed in human bone, where it was 
detected in osteocytes and osteocytic lacunae, but not in osteoblasts or other cells.   
Since sclerostin is a potent inhibitor of Wnt signaling, we hypothesized that an increased 
expression of sclerostin could explain the reduced Wnt activity in fractures. However, the 
experimental results did not support this hypothesis.  In fact, patients with fractures had 
sclerostin serum levels similar to control individuals and patients with hip OA. Moreover, 
SOST expression and the proportion of sclerostin-positive lacunae were lower in bone samples 
from patients with fractures. This result appeared counterintuitive at first sight and suggested 
the existence of an abnormal osteocyte activity in fractures. In fact, when we analyzed other 
genes typically expressed in osteocytes, such as PHEX and FGF23, they were also found to be 
down-regulated in fractures.  Osteocytes derive from osteoblasts, which become embedded 
into bone matrix when new bone is laid down and stay there inside the osteocytic lacunae. We 
found similar lacunae density in the three groups of subjects, suggesting that similar numbers 
of osteocytes were generated during the bone formation phase. However, the proportion of 
empty lacunae was higher in fractures. Since the lacunae were initially formed around an 
osteocyte, it suggested that osteocyte death was more frequent in fracture samples. Indeed, we 
found a higher proportion of lacunae staining positively for activated caspase 3, which is 
consistent with increased apoptosis of osteocytes. 
Loading experiments in rats have shown that osteocyte apoptosis takes place in regions of 
bone with microcracks and is necessary to initiate intracortical bone remodelling in response to 
fatigue microdamage [16;17]. Osteocyte apoptosis, which progresses over several days, has 
also been observed in the vicinity of macroscopic bone lesions [18]. However, apoptosis 
occurring post-fracture is unlikely to explain the differences between patients and controls. 
First, Power et al. have recently reported that sclerostin expression may be locally decreased in 
osteocytes within 0.5 mm of a bone fracture, but is not altered in those located more distant 
[19]. We did not include tissue close to the fracture site, but used bone samples more than 5 
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mm away of fracture. Second, we did not find any relationship between time elapsed since 
fracture until surgery and gene expression or osteocyte apoptosis. 
 Osteocytes appear to play a critical role in mechanotransduction, and are involved in the 
anabolic response of bone to physical forces [6;20]. In fact, osteocytes have been postulated as 
the central “metabolostat”, integrating and orchestrating a response to different mechanical 
and humoral factors acting on bone [21]. In studies with a transgenic mouse that expressed the 
receptor for diphtheria toxin in osteocytes, Tatsumi et al showed that the ablation of osteocytes 
caused an acute increase in bone resorption and cortical microfractures [20], suggesting that 
osteocyte deficiency may result in osteoporosis. Therefore, it is tempting to speculate that the 
increased osteocyte apoptosis that we observed in patients with hip fractures actually played a 
role in determining fracture risk. This is in line with a recent report showing a increased 
number of empty lacunae in a sheep model of osteoporosis [22]. 
However, the increased apoptosis of osteocytes was not the only factor contributing to the 
reduced expression of osteocytic genes in fractures. In fact, the proportion of osteocyte-
occupied lacunae which stained positively for sclerostin was lower in fractures than in 
controls. Furthermore, while the proportion of empty lacunae was about 10% higher in patients 
with fractures than in controls, the average SOST expression was reduced by more than 50%, 
and the expression of FGF23 and PHEX was decreased even further, down to less than 5% and 
30% of control values, respectively. Therefore, we can speculate about the existence of some 
factors inhibiting the expression of these genes in the osteocytes of patients with fractures. 
They might include intrinsic factors, such as genetic or epigenetic signatures, or extrinsic 
factors, such as hormones, paracrine soluble factors and matrix constituents. In this regard, it is 
interesting to note that the degree of calcification and other characteristics of the matrix 
surrounding osteocytic lacunae have been suggested to modulate the osteoblast-osteocyte 
transition [23]. We explored whether osteocyte distribution within bone, and particularly, the 
depth of the location of osteocytic lacunae, influenced sclerostin expression. That appeared to 
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be the case. Consistently with other reports [7;11;23], sclerostin-positive lacunae tended to be 
located in deeper bone layers than sclerostin-negative lacunae. As osteocytes in deeper lacunae 
are probably older, and deep bone layers are more mineralized than the superficial ones, it 
suggests that a long time and/or a well mineralized matrix are needed for these cells to fully 
differentiate and acquire the ability to produce sclerostin. However, no differences in osteocyte 
depth distribution were found between the three groups of subjects.  
Mechanical stimuli and PTH have been shown to inhibit sclerostin synthesis in vitro and in 
vivo [24-28]. Given the reduced bone mass and thinner trabeculae of patients with fragility 
fractures, it could be speculated that each individual osteocyte may be exposed to a higher 
mechanical stress in patients destined to sustain a hip fracture, which in turn could tend to 
decrease sclerostin expression. Studies combining microstructural and gene expression 
analyses could confirm or refute this contention, but it is consistent with studies showing 
increased levels of sclerostin in patients with high bone mass [29]. Vitamin D insufficiency 
and increased levels of PTH are common in patients with hip fractures [30], and would tend to 
decrease sclerostin expression. Unfortunately, we did not analyze serum PTH levels and 
therefore do not know if they were correlated with sclerostin circulating levels or expression, 
as suggested in other studies [31;32]. Although we found striking between-group differences 
in bone sclerostin at the mRNA and protein levels, there were no significant differences in 
circulating sclerostin. Therefore, serum levels do not appear to reflect adequately the bone 
microenvironment situation. In fact, counterintuitive positive associations between bone 
mineral density and serum sclerostin levels have been reported in several studies [32;33]. In 
order to explain these unexpected results, it should be realized that serum levels are the 
product of two factors: on the one hand, the expression level at each osteocyte; on the other 
hand, the total number of osteocytes, which is generally associated with the bone tissue mass 
of the individual. Therefore, osteoporotic patients with a low bone mass may have lower 
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number of osteocytes and consequently they may show a trend to lower circulating levels of 
osteocyte-derived factors.   
FGF23 expression was markedly decreased in patients with hip fractures. Its influence on 
skeletal homeostasis is unclear. It has been shown that PTH stimulates FGF23 expression in 
osteocytes, by Wnt-dependent and independent mechanisms. FGF23,  in turn, may act on the 
parathyroids inhibiting the  secretion of PTH [34;35]. Therefore, in theory the reduced 
expression of FGF23 could contribute to increase PTH levels in patients with hip fractures. 
Our study has some limitations. First, we studied trabecular bone, which may behave 
differently from cortical bone. Nevertheless, Power et al recently studied sclerostin expression 
in the femoral neck cortex and found a non-significant trend to higher sclerostin-negative 
lacunae in hip fractures than in hip osteoarthritis [36]. Second, although our results do not give 
support for the hypothesis of an increased sclerostin expression in hip fractures, a single time 
point study like this cannot exclude the possibility that previous exposure to high local levels 
of sclerostin may have played a role in increasing bone fragility. Third, we studied femoral 
heads of Caucasian individuals and do not have data about expression levels in other skeletal 
regions, but some reports suggest that there may be subtle and incompletely elucidated 
differences in osteocyte status depending on the bone region studied, as well as on the ethnic 
background of the individuals [37;38]. In any case, our results are in line with a recent report 
showing a reduced sclerostin expression in iliac crest biopsies of male patients with idiopathic 
osteoporosis [39]. Sex and age distribution was somewhat different across the study groups, 
reflecting the epidemiological differences between fractures and OA. Although patients with 
fractures tended to be older than those with OA, age difference did not appear to influence the 
results because we found no correlation between age and sclerostin expression in either group. 
Mirza et al recently measured serum sclerostin levels in women and found no correlation with 
age either [31]. On the other hand, we did not find significant sex-related differences in the 
parameters studied. 
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Interestingly, although osteocyte numbers were not decreased in patients with hip OA, SOST 
and FGF23 (but not PHEX) expression was lower in OA than in controls. These results are in 
line with a recent report by Appel et al [40] who showed a decreased  proportion of sclerostin-
positive osteocytes  in the spinal joints of patients with OA. Although unproved, it can be 
speculated that a decreased expression of SOST might play a role in the local bone formation 
responsible for the osteophytes which typically appear in OA. 
 
In summary, this study shows that osteocyte activity is altered in patients with hip fractures, 
with increased osteocyte apoptosis and reduced osteocyte numbers, as well as decreased 
transcription of several osteocyte-derived bone-regulating genes. Overall, these results suggest 
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Fig 1. Sclerostin serum levels measured by ELISA. Individual and mean values in each group. 
Frx, fractures; OA, osteoarthritis. 


























Fig, 2. Relative gene expression in bone samples. SOST, FGF23 and PHEX transcripts were 
measured by RT-qPCR in bone tissue samples from control individuals, patients with hip 
fractures (Frx) and hip osteoarthritis (OA). Bars represent mean and SD expression values 
relative to the housekeeping gene TBP in a log2 scale.  P values of the differences across 































Fig. 3. Distance from sclerostin-positive and sclerostin-negative osteocytic lacunae to the 
closest bone surface in each group (mean and SE in control samples; hip fractures –Frx-, and 
hip osteoarthritis -OA). Black bars, sclerostin-positive; dashed bars, sclerostin-negative 




















Fig. 4. Sclerostin-positive lacunae, occupied lacunae (ie, lacunae with an osteocyte) and 
lacunae with activated caspase 3 staining  in bone samples of different groups. Graphs 
represent the mean and SE percentages over total number of lacunae. Representative sections 
stained with anti-sclerostin (top) or anti-caspase 3 antibody (bottom). The arrows mark some 
positive (black arrow) and negative (white arrow) lacunae. The middle panel shows a section 











Fig 5.  Multi-axis radial graph summarizing gene expression of SOST, FGF23 and PHEX; 
occupied lacunae (Ocy number); caspase-positive lacunae (Ocy apoptosis); and lacunae 
density in patients with hip fractures (continuous line) and hip osteoarthritis (dashed line). 
Results are expressed as percentages of the values in control bone samples, which are 
represented by the grey  area.  
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